Analysts Offer Predictions for AC Immune FY2026 Earnings

AC Immune (NASDAQ:ACIU) – Analysts at HC Wainwright upped their FY2026 earnings estimates for shares of AC Immune in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.60) per share for the year, up from their prior estimate of ($0.84). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.84) per share.

Several other equities research analysts have also recently commented on the company. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, AC Immune has a consensus rating of “Hold” and a consensus target price of $7.50.

AC Immune Stock Down 3.4%

NASDAQ:ACIU opened at $2.28 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93. The company has a market cap of $232.04 million, a PE ratio of -4.22 and a beta of 1.59. AC Immune has a 52-week low of $2.03 and a 52-week high of $4.00. The stock has a 50-day simple moving average of $2.36 and a 200 day simple moving average of $2.75.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. The firm had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.

Institutional Trading of AC Immune

A number of large investors have recently added to or reduced their stakes in ACIU. Marshall Wace LLP bought a new position in shares of AC Immune in the 4th quarter valued at about $586,000. Dimensional Fund Advisors LP lifted its stake in AC Immune by 20.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after purchasing an additional 36,353 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in AC Immune in the 3rd quarter valued at about $63,000. Acadian Asset Management LLC grew its holdings in AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the period. Finally, EFG International AG acquired a new position in AC Immune during the fourth quarter worth approximately $41,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

Insider Buying and Selling at AC Immune

In related news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at approximately $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.